GRPR and prostate carcinoma: Since Doxil, liposomal DOX (Figure 9a), was launched, researchers have continued the dynamic exploration of the field of liposomal and micellar formulations to search for further improvements, one of those being active targeting of GRPR-overexpressing tumors, such as prostate cancer [39] or small-cell lung cancer [59].